{
    "clinical_study": {
        "@rank": "157907", 
        "acronym": "CYPRESS", 
        "arm_group": {
            "arm_group_label": "Cyclosporine A", 
            "arm_group_type": "Other", 
            "description": "All patients will receive Cyclosporine A in a dose of 2mg/kg/BW daily for 16 weeks"
        }, 
        "brief_summary": {
            "textblock": "Sandimmun optoral (Cyclosporin A) is used for the musculoskeletal manifestations of Primary\n      Sj\u00f6gren Syndrome"
        }, 
        "brief_title": "Low Dose Cyclosporin A in Primary Sj\u00f6gren Syndrome", 
        "completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Sj\u00f6gren\u00b4s Syndrome", 
        "condition_browse": {
            "mesh_term": "Sjogren's Syndrome"
        }, 
        "detailed_description": {
            "textblock": "NSAR are used currently for the treatment of musculoskeletal manifestations at Sj\u00f6gren\n      Syndrome for the symptomatic release of pain. For therapy-resistant cases drugs also used in\n      Rheumatoid Arthritis are used. For these drugs there is no registration for the treatment of\n      Sj\u00f6gren Syndrome."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diagnosis of a primary Sj\u00f6gren\u00b4s Syndrome\n\n          -  Liver values above 1,5 ULN\n\n          -  uncontrolled arterial hypertension\n\n          -  intraarticular or systemic use of Glucocorticoids in the last 4 weeks before\n\n          -  begin with Study medication\n\n        Exclusion Criteria:\n\n          -  pre-treatment with Cyclosporine A\n\n          -  Infection\n\n          -  Neoplasia\n\n          -  relevant cardiac, pulmonary, neurologic or psychiatric disease\n\n          -  life-Vaccination within 4 weeks before begin with study medication\n\n          -  pregnant or breast-feeding\n\n          -  weight under 45kg or more than 110kg"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 14, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01693393", 
            "org_study_id": "COLO400BDE02T"
        }, 
        "intervention": {
            "arm_group_label": "Cyclosporine A", 
            "description": "Patients will receive Cyclosporine A in a dose of ca. 2mg/kg/BW daily for a 16 week period", 
            "intervention_name": "Cyclosporine A", 
            "intervention_type": "Drug", 
            "other_name": "Sandimmun optoral"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Cyclosporins", 
                "Cyclosporine"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "primary Sjogren\u00b4s Syndrome", 
            "Cyclosporine"
        ], 
        "lastchanged_date": "May 7, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Berlin", 
                    "country": "Germany", 
                    "zip": "10117"
                }, 
                "name": "Charite Universit\u00e4tsklinikum Berlin Campus Mitte"
            }
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase II Pilot-Study With Low-dose Sandimmun Optoral (Cyclosporin A) for the Treatment of Primary Sj\u00f6gren Syndrome", 
        "other_outcome": [
            {
                "measure": "Study the general health changes and improvement of Sicca-symptoms", 
                "safety_issue": "No", 
                "time_frame": "16 weeks"
            }, 
            {
                "measure": "Documentation of improvement of articular manifestations by ultrasound examination", 
                "safety_issue": "No", 
                "time_frame": "16 weeks"
            }
        ], 
        "overall_official": {
            "affiliation": "Charite University, Berlin, Germany", 
            "last_name": "Eugen Feist, Dr. med.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Examination of the therapeutic effects (improvement in number of tender, swolen joints, DAS 28) of low dose Cyclosporine A in patients with primary Sj\u00f6gren Syndrome and articular involvement after a treatment-phase of 16 weeks.", 
            "safety_issue": "No", 
            "time_frame": "16 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01693393"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Charite University, Berlin, Germany", 
            "investigator_full_name": "Eugen Feist", 
            "investigator_title": "PD. Dr. med. Eugen Feist", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "Evaluation of the safety (type and number of adverse events and serious adverse events) of low-dose Cyclosporine A in patients with primary Sj\u00f6gren Syndrome", 
            "safety_issue": "Yes", 
            "time_frame": "28 weeks"
        }, 
        "source": "Charite University, Berlin, Germany", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Charite University, Berlin, Germany", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2010", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}